| Summary: | Knowledge of human papillomavirus transmission from the genital tract to the oral mucosa remains unsatisfactory, with poor and often inconsistent literature results. The increase in HPV-associated oral malignancies prompts further analysis of the simultaneous detection of the virus in the two anatomical areas and on the identification of genotypes to be included in future vaccines. Therefore, in this retrospective study, we evaluated orogenital HPV concurrence, hrHPV, lrHPV and type-concordance in 337 samples, as well as the prevalence of the most common genotypes not included in HPV vaccines. Concurrence was found in 12.5% (31/248) of cases, hr-concordance in 61.3% (19/31) and lr-concordance in 12.9% (4/31). Finally, type-concordance was found in 32.3% (10/31) of concurrent infections. Regarding the identification of non-vaccine genotypes, the significantly prevalent genotypes in the anogenital area were HPV66 (12.6%, <i>p</i> < 0.0001), HPV53 (11.1%, <i>p</i> < 0.0001), HPV51 (8.7%, <i>p</i> < 0.0001), HPV42 (8.2%, <i>p</i> < 0.0001) and HPV68 (5.6%, <i>p</i> = 0.0034) in women and HPV66 (14.6%, <i>p</i> = 0.0058), HPV42 (12.2%, <i>p</i> = 0.0428), HPV51 (12.2%, <i>p</i> = 0.0428), HPV53 (12.2%, <i>p</i> = 0.0428), HPV70 (12.2%, <i>p</i> = 0.0428) and HPV73 (12.2%, <i>p</i> = 0.0428) in men. Considering the results of our study, we recommend including the high-risk genotypes HPV51, HPV68, HPV53 and HPV66 in future HPV vaccine formulations.
|
|---|